# Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients

> **NCT00189345** · PHASE2 · COMPLETED · sponsor: **AGO Study Group** · enrollment: 44 (—)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms

## Interventions

- **BIOLOGICAL:** anti-EpCAM x anti-CD3 (removab)

## Key facts

- **NCT ID:** NCT00189345
- **Lead sponsor:** AGO Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** —
- **Final completion:** 2005-10
- **Target enrollment:** 44 (—)
- **Last updated:** 2006-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00189345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00189345, "Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00189345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*